The conversion of angiotensin I to angiotensin II was studied in vivo in the intact anesthetized dog and in vitro in whole blood and plasma treated with various anticoagulants by fractionation of radioactively labeled peptides and by radioimmunoassay. After injection of angiotensin I into the pulmonary artery at 10,000 times the physiologic level, approximately 50% of the injected material was recovered in the aorta. Fifty three percent of the material recovered had been converted to angiotensin II, as measured both by peptide release and by radioimmunoassay. Following injection of 1000 to 10,000 times physiologic levels of angiotensin I into the renal artery, 7 to 104 of the immunoreactive material in the venous effluent after a single circulation time was angiotensin II. There was no evidence of conversion in the liver or hindlimb. Conversion in vitro was far slower than in vivo, the half-life in fresh blood being 3 minutes, with longer times observed in anticoagulated plasmas. The major metabolite of in-vivo conversion was leucine, of in-vitro conversion, histidyl leucine. These observations indicate that the major site of conversion of angiotensin I to angiotensin II is in the pulmonary capillary bed. The kidnev may participate as a secondary site. Conversion in plasma probably plays no important physiologic role. The mechanism of organ and plasma conversion may differ, as indicated by the different metabolites.
tensin I to angiotensin II in vitro and in vivo using radioactive tracer techniques and the radioimmunoassay for angiotensin I and II.
Methods
The metabolism of synthetic lieu 5 S H-Leu 10 angiotensin I ( S HAI) 1 (188 mc/mmole, lot 307-188) was evaluated in plasma, whole blood, and in the intact dog. The conversion of angiotensin I to angiotensin II in whole blood and in the intact dog was examined by radioimmunoassay techniques (8, 9) . Samples (15 ml) of blood were drawn from the femoral arteries of pentobarbital-anesthetized dogs into iced 20-ml glass tubes variously containing heparin, 143 USP units, sodium citrate, 0.5 ml of 3.8% solution, and the disodium salt of ethylene diamine tetraacet i c acid (EDiDonated by the New England Nuclear Corporation. Unlabeled angiotensin I was donated by Schwarz Bio Research.
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TA), 1 ing/ml (Becton Dickinson). Samples were spun immediately at 4°C in a refrigerated centrifuge and the plasma fraction was removed and frozen. Samples of human venous plasma were prepared similarly. 8 HAI (200 fi^itnoles) was added to 1 ml of plasma and incubated in a water bath at 37°C, Aliquots of 50 ^.liters were removed at 10, 15, 20, 30 and 60 minutes and 2, 4 and 24 hours. Plasma was spotted on Whatman 3MM Paper and subjected to electrophoresis (Savant Co.) at 2000 volts for 3 hours in pyridine acetate buffer at pH 3.5. The paper was dried, cut into half-inch strips, and counted under Bray's solution in a liquid scintillation counter (Ansitron). Peptides were identified by comparison with known HAI, histidyl leucine, and leucine.
Whoto Blood
Samples of 60 ml of arterial blood from three dogs anesthetized with pentobarbital (15 mg/kg) were drawn without anticoagulant into two 30-ml siliconized plastic syringes containing 6 m^imoles of 3HAI. The final concentration of "HAI was 250 to 300 /i / xmoles/ml plasma. At 10, 15, 20, 30, 40 and 60 seconds and 2, 3, 5, 10 and 15 minutes 5-ml aliquots were added to iced tubes containing a mixture of enzyme inhibitors, resulting in a final concentration of 2.6 ITIM EDTA, 1.6 mM dimercaptol (BAL), and 3.4 mM 8-OH quinoline. This combination has been shown (8) to be effective in inhibiting angiotensin I conversion and angiotensinase activity in plasma. The dog plasma was separated and stored in the manner described above. Because of the large volume of plasma and the large number of samples to be processed, a more rapid analytical technique was evolved. The peptides were concentrated on Dowex and subsequently separated on SE Sephadex and on the sulfonated polystyrene resins of the amino acid analyzer (Beckman). Plasma was acidified to pH 1.5 with IN HC1, diluted 1:4 widi distilled water, and passed through 2 X 50 mm columns of Dowex 50 X-2, which was in the H form. The Dowex had been prepared by washing with 0.1N HC1 and then with distilled water until the pH of the effluents returned to 4.0. Labeled peptides were eluted from the columns widi 0.2N NH 4 0H and 0.1N diethylamine. Eighty-five to 90* of the radioactivity applied was recovered. Eluates were divided into two parts and dried. To separate HAI from smaller labeled peptides and leucine, half of each sample was passed through a 2 X 50 mm column of SE Sephadex C 25 which had previously been equilibrated with O.OIN acetic acid. A sodium acetate buffer system was used for stepwise elution of peptides. Leucine and histidyl leucine were eluted completely at pH 4.5 with 0.06M buffer and HAI at pH 8.0 with 1.0M sodium acetate. Recovery from these columns was 90 to 97%. To separate leucine from histidyl leucine, the remainder of each sample was run on the short column of an amino acid analyzer, using an 8% cross-linked sulfonated polystyrene resin (AA-27, Beckman) with citrate buffers at pH 2.2 and 5.28. Effluents from both columns were collected and counted with Bray's solution in a liquid scintillation counter (Ansitron). Counts were corrected for quenching using a 1S7 Cs external standard. To establish the validity of substituting column for electrophoretic separation, column eluates were subjected to electrophoresis with standards under the conditions specified above. Peptide identification and quantification were identical in both. An aliquot of plasma from each sample was subject to radioimmunoassay for angiotensin I and II. The antibodies used in these assays have been shown to have less than 5% cross reactivity.
The metabolism of s H-L-histidyl-L-leucine ( S H-HL) (150 mc/mmole, New England Nuclear) in whole dog blood was evaluated by a similar procedure. The sulfonated polystyrene resin AA-15(Beckman) on the long column of an amino acid analyzer with citrate buffers of pH 2.2, 3.26, and 4.25 was used to separate histidine from histidyl leucine.
IN VIVO
In 27 mongrel dogs of both sexes weighing 20 to 30 kg and anesthetized with pentobarbital, 15 mg/kg, catheters were placed in main pulmonary artery, ascending aorta, inferior vena cava, hepatic vein, renal artery, and renal vein under fluoroscopic control and in portal vein and femoral artery and vein under direct visualization. Anticoagulants were not given; catheters were kept open with frequent saline flushes. Blood pressure was continuously monitored from a large-bore catheter in the descending aorta by a pressure transducer (Hewlett-Packard) and recorded on a 6-channel direct-writing oscillograph (Hewlett-Packard). Circulation times were measured by injecting a bolus of indocyanine green dye into the pulmonary artery and withdrawing blood from the central aorta through a Gilford densitometer with a Harvard constant-withdrawal pump.
8 HA1, 100 myxmoles, was injected as a single bolus into the pulmonary artery of five dogs and the portal vein of four dogs. 8 sequential 15-ml aliquots from the corresponding veins at 5-second intervals following 3 HAI injection. A series of glass syringes connected via a manifold system and containing EDTA, BAL, and 8-OH quinoline in the amounts described above were used for collection. Samples were processed and analyzed as described for whole blood above. Samples 2 and 3 obtained 5 to 15 seconds after injection represented one circulation through die lung, kidney, or lower extremity as detenrlined by appearance time of labeled peptide; samples 4 and 5 obtained 15 to 25 seconds after injection represented one circulation through the more sluggish hepatic portal bed. Since the systemic circulation times of the dogs averaged 20 ± 2 seconds, significant recirculation was unlikely. As a control, arterial blood from each experimental animal was exposed to concentrations of HAI comparable to those measured in the effluent for a time equal to a single circulation time of the organ under study. Control samples were processed m a manner identical to the experimental samples. To avoid interference with residual radioactivity, each dog was given only one injection.
The conversion of unlabeled synthetic lieu 5 angiotensin I (Schwarz Bio-Research) to angiotensin II was evaluated in the pulmonary and renal capillary beds. Angiotensin I was injected as a single bolus of 100 m^imoles into the pulmonary artery of two dogs, 60 m^imoles into the renal artery of four dogs, 20 myttmoles into the renal artery of four dogs, and 10 myxmoles into the renal artery of four dogs. The high doses gave blood levels of angiotensin I and II comparable to those achieved with the radioactive peptides as described above. Blood was collected from the corresponding veins and the plasma separated and assayed direcdy for angiotensin I and II as previously described. No extraction procedures were employed. Apparent percent conversion was arrived at by subtracting the percent of counts representing angiotensin I from 100.
Results

Figure 1 summarizes the metabolism of
Whok Blood
The time course of 8 HAI metabolism in whole dog blood with no anticoagulant is summarized in Table 1 . The half-life for survival of 3 HAI in this system was 3 minutes. Angiotensin I breakdown occurred to the extent of only 8% in 15 seconds (an average circulation time). Three-fourths of the 3 HAI was metabolized in 5 minutes. As in plasma with anticoagulant histidyl leucine was the first metabolite to appear. Results were consistent for the three blood samples analyzed.
The evaluation of the same samples by radioimmunoassay for angiotensin I and II is also summarized in Table 1 . For intermediate incubation times (30 to 300 seconds), only a small percent of the immunoreactive material appeared as angiotensin II. This contrasts with the more rapid appearance of radioactive breakdown products measured by tracer techniques. Angiotensinase activity may account for the predominance of degradation products over intact angiotensin II in the incubates.
Tritiated histidyl leucine was degraded rapidly in whole blood (Table 2 ). Its half-life was 40 seconds. Destruction was nearly complete in 5 minutes.
IN vivo
Only 47 ± 3$ of the radioactive material appearing in the effluent after a single passage through the pulmonary circulation was unchanged angiotensin I. The remainder was leucine and histidyl leucine in a ratio of 4 to 1.
No other labeled peptides were recovered. Table 3 summarizes the results for five experimental animals. The recovery of labeled materials in 60 ml of the pulmonary venous effluent over a 20-second collection period was 4 to 6% of the total radioactivity administered -For the first three dogs studied, pulmonary blood flow was measured by indocyanine green dye dilution. The aliquot collected represented 8 to 11 % of the pulmonary blood flow during the collection period, allowing computation of the total amount of radioactivity leaving the lungs. After a single passage through the lungs 50 to The uncorrected values represent direct measurements of radioactively labeled peptides. The corrected value is arrived at by subtracting the percent conversion which would occur in dog blood at 37° in a'comparable period of time. The mean value ± 1 SE is given for each experimental group. 
min 5 min
TIME AFTER INJECTION
FIGURE 2
Pressor response after "HAI injection into the pulmonary artery. The arrow represents the time of injection. Diastolic pressure begins to rise at 12 seconds, corresponding to one circulation time through the lung. Pressor response lasts for 3 minutes.
55% of the radioactivity injected was recovered.
All dogs had -a pressor response (Fig. 2 ) within 15 seconds after injection of angiotensin I which lasted for approximately 3 minutes. Systolic pressures increased by a mean of 60 ± 18 mm Hg; diastolic pressures increased by a mean of 51 ± 13 mm Hg. Control infusions of equal volumes of saline into the pulmonary artery produced no pressor response. In two control studies in Circulation Rtsurcb, Vol. XXVI, Msy 1970 which angiotensin I was infused into the inferior vena cava and collected from the clamped pulmonary artery, all radioactivity recovered was in the form of unchanged angiotensin I. No pressor response was seen in these animals.
Of the 8 HHL recovered from the pulmonary effluent 5O3> (47 and 53% in two animals) was degraded in a single circulation time, and 50$ of the total radioactivity injected was recovered. Less than 10% degradation was The quantities of angiotensin I and II are expressed as wunoles/ml plasma and as percents of total immunoreactive activity in each sample. The range of absolute values and the mean percent ±1 BE are given for each experimental group. seen after injection into the inferior vena cava and recovery from the clamped pulmonary artery.
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In the renal circulation, 80% of the radioactive material recovered from venous blood after one passage was intact angiotensin I. The remaining 20% was leucine and histidyl leucine in a ratio of 4 to 1. Table 3 summarizes the results for four animals. A pressor response was consistently seen 15 to 20 seconds after the injection of "HAL The mean systolic increase was 55 ± 22 mm Hg; the mean diastolic increase was 48 ±19 mm Hg. This was comparable in magnitude to the response after injection into the pulmonary artery.
To demonstrate that removal of labeled histidyl leucine or leucine reflected the generation of angiotensin II, radioimmunoassay was used. Table 4 summarizes the results of 14 such experiments. In two experiments, infusion of 100 m/umoles of angiotensin I into the pulmonary artery yielded 192 to 212 /x/xmoles of angiotensin I and 275 to 300 fifimoles of angiotensin II per ml of plasma after a single passage through the lung. This represents 545 conversion and 50% recovery at 10,000 times physiologic levels, reproducing the results obtained by measurement of radioactive peptides. In contrast, infusion of 60 m/imoles (high dose) of angiotensin I into the renal artery yielded 98 to 555 /x/imoles of angiotensin I and only 7 to 29 fi^imoles of angiotensin II per ml of renal vein plasma after a single circulation. This represents a barely detectable 1% conversion, contrasting with 202 breakdown seen in the radioactive peptide studies.
After infusion of 10 and 20 m/xmoles (low dose) of angiotensin I into the renal artery, 41 to 100 /i/imoles of angiotensin I and 5 to 13 /x/xmoles of angiotensin II were recovered per ml of renal vein plasma. There was 9% conversion at 1000 times physiologic levels. A pressor response was consistently observed 15 to 20 seconds after injections of both high and low doses into the renal artery. Mean systolic and diastolic increases after the high-dose injections were 52 ± 24 and 47 ± 16 mm Hg; after low-dose injections, 37 ± 13 and 29 ± 19 mmHg. Conversion in the hindlimb and in the hepatic portal circulation was not detected at the doses of infused S HAI used in this study (Table 3) . A pressor response was seen in these animals 15 to 25 seconds after injection, probably reflecting intrapulmonary conversion. The magnitude of increase in blood pressure was comparable to that seen in the transpulmonary experiments: 57 ± 12 mm Hg systolic and 52 ± 17 mm Hg diastolic for hindlimb and 49 ± 26 mm Hg systolic and 51 ± 14 mm Hg diastolic for liver.
Discussion
This study has given chemical evidence that angiotensin I is converted to angiotensin II in the pulmonary and renal circulations of the dog at a rate that is too rapid to be accounted for by plasma conversion alone. Within 15 seconds of injecting a large bolus of angiotensin I into the pulmonary artery, high levels of angiotensin II were measurable by radioimmunoassay in aortic blood. After injecting comparable amounts of angiotensin I into the renal artery, lower but still supraphysiologic 
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levels of angiotensin II appeared in renal venous blood. Leucine and to a lesser extent histidyl leucine appear in both pulmonary and venous effluents as metabolic products of angiotensin I. Under the conditions of this experiment, appreciable quantities of angiotensin II, leucine, or histidyl leucine were not observed in effluent blood of the hepatic portal system or the hindlimb of the dog.
Our finding of extensive conversion in the intact pulmonary circulation confirms the observations of others (3-7) using bioassay techniques. Angiotensin I conversion has been found in the lungs of dog, rat, cat, rabbit, and man using both equine and synthetic angiotensin I as substrate. Isolated lungs perfused with a plasma-free system also convert angiotensin I to II, but to a lesser extent than the intact organ (10) . In addition, angiotensin Iconverting activity has been demonstrated in cell-free extracts of lung tissue (11) . Thus, the lung is considered the principal site of formation of circulating angiotensin II (3).
Extrapulmonary angiotensin I conversion has been demonstrated in vitro by bioassay and radioactive tracer techniques. Plasma (12) and extracts of several organs of the rat, including kidney, ileum, liver, heart, and brain, as well as the* lung (13) , have converting enzyme activity, the physiologic significance of which is questionable. Other workers (14) have found partial preservation of the systemic pressor response to infused angiotensin I in the dog after exclusion of the lungs from the circulation by cardiopulmonary bypass. The extent of preservation suggested that about one-third of overall conversion normally occurred in extrapulmonary sites. No further localization was achieved.
Angiotensin I conversion has not been demonstrated in femoral, carotid, renal, or total peripheral vascular beds of the intact animal or the isolated perfused kidney by the blood-bathed organ technique (4, 10) . Angiotensin II inactivation has been demonstrated in intact (4, 10, 15) and isolated perfused (16) kidneys. This could mask angiotensin I conversion as detected by bioassay, which depends on the presence of angiotensin II in CircmUiion Research, Vol. XXVI, Mr, 1970 renal vein blood. A further explanation for this may be nonspecific damage to the conversion system in the process of surgically removing and artificially perfusing the kidney. Evidence of such organ damage was seen in the lung, in which the percent conversion of a given infusion of angiotensin I decreased from 80 in the intact organ to 20 in the isolated perfused preparation (10). In our study, angiotensin I metabolism took place in kidney to a lesser extent than in lung. At high concentrations of angiotensin I, of the order of 300 /x/tmoles/ml, over 50% of an infused dose of 8 HAI was broken down by the lung but only 20% by the kidney. When unlabeled angiotensin I was infused in comparable concentrations, over 50% of the immunoreactive material in the pulmonary effluent was angiotensin II, while only 7% of that in renal vein was angiotensin II. When the quantity of angiotensin I was reduced by a factor of 10, the percent conversion to angiotensin II in the kidney increased only to 10. The predominance of breakdown over conversion in the kidney is compatible with the rate of nonspecific breakdown of peptides exceeding the rate of conversion of angiotensin I to II or selective sequestration of angiotensin II. The intrarenal fate of infused angiotensin I bears on the question of renal autoregulat i on. Further study of the isolated renal circulation is necessary to clarify this question.
Histidyl leucine was the primary product of in-vitro conversion in both plasma and whole blood. Plasma conversion was slowed to a minor extent by citrate and markedly by EDTA. This is in agreement with observations by Skeggs et al. (12) on converting enzyme isolated from horse plasma. In their study the enzyme cleaved specifically the Phe s -His°b ond in angiotensin I, yielding histidyl leucine and angiotensin II. It is a heavy metal dependent enzyme which can be partially inhibited by EDTA. It acts slowly, requiring 6 hours to completely convert a given quantity of angiotensin I in a plasma-free system at 37°C. Huggins and Thampi (13), using organ extracts and a radioactive tracer technique, confirmed the generation of histidyl leucine in the conversion process. The conversion of angiotensin I in fresh whole blood was more rapid than in previously frozen plasma. This may be related to the instability of converting enzyme, to partial inhibition by the anticoagulants, or to the contribution of converting enzyme by the formed elements. Our results derived from radioactive peptide measurements were comparable to those of Ng and Vane (3) with heparinized whole blood for short incubation times (8 vs. 14% conversion at 15 seconds; 44 vs. 29$ at 1 minute). Conversion appeared to be incomplete, even after 15 minutes of incubation. This may have been due to simultaneous destruction by angiotensinases or to impurities in the synthetic angiotensin I, as suggested by Ng and Vane (3).
Leucine was four times as abundant as histidyl leucine after a single passage through both lung and kidney. The half-life of histidyl leucine in whole blood was about 40 seconds, and only half of the histidyl leucine infused into the pulmonary artery was broken down in a single circulation time through the lungs. This suggests that the appearance of leucine is too rapid to be accounted for by secondary breakdown of histidyl leucine cleaved from angiotensin I. The question of another enzymatic method of conversion must be raised, such as stepwise removal of amino acids by a carboxypeptidase. A less likely possibility is that leucine and histidine might be removed by two separate enzymes.
It is clear from our investigation that the dog lung has the capacity to convert in a single passage across its capillary bed a dose of angiotensin I that is 10,000 times the physiologic concentration. The kidney has a smaller capacity for converting angiotensin I. Neither conversion nor breakdown is seen in hindlimb or hepatic portal circulations at high levels of angiotensin I. Conversion occurs much more slowly in plasma or in fresh blood with no anticoagulant than in the intact organism. Plasma conversion may therefore be of little physiologic importance. Preliminary data suggest that the chemical mechanisms of conversion in lung and kidney may differ from those in circulating blood.
